Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and refreshing, because the familiar routine of online calls and deadlines has, predictably, returned. But what can you do? The world keeps spinning, no matter how hard we try to slow it down. So to cope, we are firing up the coffee kettle and brewing cups of stimulation. Our choice today is salted caramel mocha — a taste of the Jersey shore. Meanwhile, here are some tidbits. Hope your day goes well and you conquer the world…

Shionogi (SGIOY) has started human trials of the first once-a-day pill for Covid-19 patients, joining Pfizer (PFE) and Merck (MRK) in the race to find treatments for the disease, The Wall Street Journal tells us. The company said the once-a-day dosing would be more convenient and began trials this month that are likely to continue until next year, but  is months behind Pfizer and Merck, which have started later-stage tests of their pills. Pfizer has said its twice-daily pill could be ready to hit the market as soon as this year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment